Evidence map›Paper›PMID 32152220›Full record

ArticleJournal for immunotherapy of cancer2020

Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma.

Yong Li, Yingqiu Song, Pindong Li, Mingxing Li, Haizhou Wang, Tao Xu, Xiongjie Yu, Yuandong Yu, YunYan Tai, Ping Chen and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Inhibition of LDHA promotes GSDME-dependent pyroptosis by activating RIG-I-like receptor signaling.Apoptosis : an international journal on programmed cell death · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Yong Li *Department of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Yingqiu Song *Cancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Pindong LiCancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Mingxing LiDepartment of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Haizhou WangDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Tao XuDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Xiongjie YuDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Yuandong YuDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
YunYan TaiDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Ping ChenDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Xiaojun CaiDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Xianhe WangDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Longchao XiangDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Rui DengDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Xiufang ZhangDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Liping GaoDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Xuanbin WangDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Jing LiuDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China fengjuncao@hbmu.edu.cn liujing_GI@whu.edu.cn.ORCID 0000-0002-0958-5506
Fengjun CaoDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China fengjuncao@hbmu.edu.cn liujing_GI@whu.edu.cn.
Hubei University of Medicine · CNUnion Hospital · CNWuhan University · CNTongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterferon-α (IFN-α) plays a pivotal role in host antitumor immunity, and the evasion of IFN-α signaling pathway can lead to IFN-α resistance during the treatment of cancer. Although the interplay between IFN-α and tumor cells has been extensively investigated in differentiated tumor cells, much less attention has been directed to tumor-repopulating cells (TRCs).

methodsThree-dimentional soft fibrin matrix was used to select and grow highly malignant and tumorigenic melanoma TRCs. The regulation of integrin β3 (ITGB3)-c-SRC-STAT signaling pathway in melanoma TRCs was investigated both in vitro and in vivo. The relevant mRNA and protein expression levels were analyzed by qRT-PCR and western blot analysis. Immunoprecipitation and chromatin immunoprecipitation (ChIP) followed by qPCR (ChIP-qPCR) assays were performed to detect protein-protein and protein-DNA interactions. The clinical impacts of retinoic acid inducible gene-I (RIG-I) were assessed in melanoma datasets obtained from The Cancer Genome Atlas and Gene Expression Omnibus profiles.

resultsIFN-α-induced apoptosis was decreased in melanoma TRCs. Compared with conventional flask-cultured cells, IFN-α-mediated STAT1 activation was diminished in melanoma TRCs. Decreased expression of RIG-I in melanoma TRCs led to diminished activation of STAT1 via enhancing the interaction between Src homology region 2 domain-containing phosphatase-1 and STAT1. In addition, low expression levels of RIG-I correlated with poor prognosis in patients with melanoma. STAT3 was highly phosphorylated in TRCs and knockdown of STAT3 reversed the downregulation of RIG-I in TRCs. Knockdown of STAT3 resulted in STAT1 activation and increased expression of the pro-apoptosis genes in IFN-α-treated TRCs. Combined treatment of STAT3 inhibitor and IFN-α increased the apoptosis rate of TRCs. Disruption of ITGB3/c-SRC/STAT3 signaling pathway significantly elevated the efficiency of IFN-α-induced apoptosis of TRCs.

conclusionsIn melanoma TRCs, ITGB3-c-SRC-STAT3 pathway caused RIG-I repression and then affect STAT1 activation to cause resistance to IFN-α-induced apoptosis. RIG-I is a prognostic marker in patients with melanoma. Combination of STAT3 inhibitor and IFN-α could enhance the efficacy of melanoma treatment. Our findings may provide a new concept of combinatorial treatment for future immunotherapy.

Indexed as

AnimalsApoptosisCell Line, TumorDEAD Box Protein 58Down-RegulationFemaleHep G2 CellsHumansImmunologic FactorsIntegrin beta3Interferon-alphaMelanomaMelanoma, ExperimentalMiceMice, Inbred C57BLPrognosisDEAD Box Protein 58Immunologic FactorsIntegrin beta3Interferon-alphaITGB3 protein, humanProto-Oncogene Proteins pp60(c-src)Receptors, ImmunologicRIGI protein, humanSTAT1 protein, humanSTAT1 Transcription FactorSTAT3 protein, humanSTAT3 Transcription Factorimmunologymedicinetumours

Identifiers

PMID32152220
PMCPMC7061898
OpenAlexW3012312104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.